Martin & Co. Inc. TN grew its position in Omnicell, Inc. (NASDAQ:OMCL) by 1.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 65,990 shares of the company’s stock after acquiring an additional 1,100 shares during the quarter. Martin & Co. Inc. TN owned 0.18% of Omnicell worth $2,844,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in OMCL. Ameritas Investment Partners Inc. bought a new stake in shares of Omnicell in the 1st quarter worth approximately $125,000. Oppenheimer Asset Management Inc. bought a new stake in shares of Omnicell in the 1st quarter worth approximately $170,000. Turner Investments LLC bought a new stake in shares of Omnicell in the 2nd quarter worth approximately $181,000. Riverhead Capital Management LLC lifted its position in shares of Omnicell by 76.3% in the 2nd quarter. Riverhead Capital Management LLC now owns 4,230 shares of the company’s stock worth $182,000 after acquiring an additional 1,830 shares during the period. Finally, Flinton Capital Management LLC lifted its position in shares of Omnicell by 74.6% in the 2nd quarter. Flinton Capital Management LLC now owns 4,216 shares of the company’s stock worth $182,000 after acquiring an additional 1,802 shares during the period.

OMCL has been the subject of a number of research reports. Dougherty & Co raised their price objective on Omnicell from $45.00 to $49.00 and gave the stock a “buy” rating in a research report on Friday, July 28th. Craig Hallum raised their target price on Omnicell from $46.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, July 28th. Cantor Fitzgerald restated a “buy” rating and set a $47.00 target price on shares of Omnicell in a research report on Tuesday, July 25th. Benchmark Co. raised their target price on Omnicell from $55.00 to $67.00 and gave the stock a “buy” rating in a research report on Tuesday, September 5th. Finally, BidaskClub downgraded Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $51.57.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/10/11/martin-co-inc-tn-increases-holdings-in-omnicell-inc-omcl.html.

In other Omnicell news, Chairman Randall A. Lipps sold 40,000 shares of the company’s stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $49.76, for a total transaction of $1,990,400.00. Following the completion of the sale, the chairman now directly owns 196,551 shares in the company, valued at $9,780,377.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Peter J. Kuipers sold 3,532 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $50.96, for a total value of $179,990.72. Following the sale, the vice president now owns 40,714 shares of the company’s stock, valued at $2,074,785.44. The disclosure for this sale can be found here. Insiders have sold 184,094 shares of company stock valued at $9,094,791 over the last 90 days. Corporate insiders own 3.77% of the company’s stock.

Omnicell, Inc. (NASDAQ OMCL) traded down 0.048% during trading on Wednesday, hitting $51.625. The company had a trading volume of 33,642 shares. The company’s market capitalization is $1.93 billion. The stock has a 50-day moving average of $50.19 and a 200 day moving average of $44.94. Omnicell, Inc. has a one year low of $30.35 and a one year high of $52.70.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, July 27th. The company reported $0.02 earnings per share for the quarter, hitting the consensus estimate of $0.02. Omnicell had a positive return on equity of 0.41% and a negative net margin of 1.14%. The firm had revenue of $180.90 million during the quarter, compared to analysts’ expectations of $174.08 million. During the same period in the prior year, the company earned $0.38 earnings per share. The company’s quarterly revenue was up 4.6% on a year-over-year basis. Equities analysts forecast that Omnicell, Inc. will post $1.30 EPS for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Stock Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related stocks with our FREE daily email newsletter.